Skip to main navigation Skip to search Skip to main content

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

  • A Spencer
  • , S Lentzsch
  • , K Weisel
  • , H Avet-Loiseau
  • , T M Mark
  • , I Spicka
  • , T Masszi
  • , B Lauri
  • , MD Levin
  • , A Bosi
  • , V Hungria
  • , M Cavo
  • , JJ Lee
  • , AK Nooka
  • , H Quach
  • , C Lee
  • , W Barreto
  • , P Corradini
  • , CK Min
  • , EC Scott
  • AA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, J C Jo, HJ Shin, Pieter Sonneveld, D Soong, T Casneuf, C Chiu, H Amin, M Qi, P Thiyagarajah, A K Sasser, JM Schecter, MV Mateos

Research output: Contribution to journalArticleAcademicpeer-review

243 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2079-2087
Number of pages9
JournalHaematologica
Volume103
Issue number12
DOIs
Publication statusPublished - 2018

Research programs

  • EMC MM-02-41-03
  • EMC MM-03-32-04

Cite this